The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial.
 
Yoshihito Ohhara
No Relationships to Disclose
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Lilly; Merck Serono; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroshi Osawa
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshiaki Shindo
No Relationships to Disclose
 
Manabu Shiozawa
No Relationships to Disclose
 
Hiroyuki Uetake
No Relationships to Disclose
 
Hiroshi Matsumoto
No Relationships to Disclose
 
Norio Ureshino
No Relationships to Disclose
 
Hironaga Satake
No Relationships to Disclose
 
Takaaki Kobayashi
No Relationships to Disclose
 
Takeshi Suto
No Relationships to Disclose
 
Shiro Kitano
No Relationships to Disclose
 
Yasuo Ohashi
Leadership - EP-Cruse Co., Ltd; Statcom
Stock and Other Ownership Interests - Statcom
Honoraria - Chugai Pharma; Daiichi Sankyo; Kowa; Sanofi; Shionogi
Research Funding - Eisai (Inst); Yakult Pharmaceutical
Travel, Accommodations, Expenses - Yakult Pharmaceutical
 
Kohei Uemura
No Relationships to Disclose
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)